CT Scans May Track Lung Disease Treatment Response

Adults with interstitial lung disease may one day have imaging-based markers that show whether antifibrotic treatment is working.

Updated on Nov. 2, 2026 in Asthma

Bold vector editorial illustration of two stacked oxblood and cream lung-shaped forms resting on a slate-blue plinth, evoking imaging-based monitoring of lung disease treatment.
Brainomix presented Phase III INBUILD substudy data showing CT imaging markers can detect nintedanib's effect in interstitial lung disease. AI Illustration. Upload story photo >

Brainomix presented new data from a Phase III INBUILD substudy showing that CT imaging biomarkers can detect the treatment effect of nintedanib, an antifibrotic drug used in interstitial lung disease. The findings suggest imaging may help identify patients at risk of progression and track whether antifibrotic treatment is working.

Why it matters

Interstitial lung diseases are hard to monitor because the regulator's primary endpoint, forced vital capacity (FVC), can be slow to reflect change. If CT-derived biomarkers can capture treatment response earlier, they could offer clinicians and patients another window into how the disease is progressing.

The findings come from a substudy within the Phase III INBUILD trial of nintedanib, with quantitative CT analysis run on two platforms, Brainomix's e-Lung and a UCLA algorithm. The source does not report sample size or effect magnitude, and the reticulovascular score's mortality prediction is reported without figures.

The players

Brainomix

A company developing AI-driven imaging software, including the Brainomix 360 e-Lung system, designed to identify interstitial lung diseases on CT scans.

Boehringer Ingelheim

A pharmaceutical company that sponsored the Phase III INBUILD trial of nintedanib, an antifibrotic treatment for interstitial lung disease.

Peter George

A consultant pulmonologist at London's Royal Brompton Hospital who co-authored the INBUILD paper and serves as Brainomix's senior medical director.

The details

Quantitative CT software examines scans to measure pulmonary features, such as the extent of lung tissue scarring, in a way that can be tracked over time. In the INBUILD substudy, measurements from two separate platforms both picked up nintedanib's effect, which suggests the signal is not unique to one tool. Brainomix's e-Lung reticulovascular score was also reported to predict later mortality on its own.

Timeline

  1. Article discussing the INBUILD biomarker results was published on November 2, 2026.

Health Landscape

Antifibrotic drugs like nintedanib slow progression in interstitial lung disease rather than reversing scarring, which makes early and sensitive measurement of response especially important. Imaging biomarkers that complement FVC could help the field move toward more responsive ways of judging whether treatment is working.

If you have been diagnosed with interstitial lung disease, it may be worth asking your pulmonologist whether imaging-based measures could be used alongside lung function tests to track your condition. These tools are still under development, so any decisions about monitoring or treatment should be made with your physician.

The takeaway

Imaging biomarkers may add a useful signal beyond lung function tests for tracking antifibrotic response. Ask your doctor whether CT-based assessment is part of your monitoring plan.

Further reading

For background on related airway conditions, explore our Asthma coverage.

Source note: This article includes information reported by Insights.